Posted by Michael Wonder on 13 Jan 2018
Roche’s Ocrevus (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
12 January 2018 - First and only approved disease-modifying medicine for people in the European Union with early primary progressive multiple sclerosis.
Roche announced today that the European Commission has granted marketing authorisation for Ocrevus (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
Multiple sclerosis (MS) affects approximately 700,000 people in Europe, of which around 96,000 have the highly disabling primary progressive form. Most people with MS have a relapsing form or primary progressive MS at diagnosis.
